Elevation Wealth Partners
JAZZ icon

Elevation Wealth Partners’s Jazz Pharmaceuticals JAZZ Stock Holding History

Elevation Wealth Partners’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$60K Buy
259
+158
+156% +$39K 0.02% 333
2026
Q2 		$24.3K Buy
+101
New +$22.1K 0.01% 522

Other funds holding JAZZ

LSV Asset Management
LSV Asset Management Chicago, Illinois $54.1B AUM 39.29% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $118B AUM 40.52% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.8B AUM 33.92% 1-Year Est. Return
Boston Trust Walden
Boston Trust Walden Boston, Massachusetts $12.4B AUM 21.62% 1-Year Est. Return
AssetMark Inc
AssetMark Inc Concord, California $59.5B AUM 15.92% 1-Year Est. Return
Polaris Capital Management
Polaris Capital Management Boston, Massachusetts $953M AUM 27.74% 1-Year Est. Return
DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $87.8B AUM 20.94% 1-Year Est. Return

Elevation Wealth Partners's JAZZ Position: Q3 2026 in Review

Elevation Wealth Partners increased its Jazz Pharmaceuticals (JAZZ) stake by 156% in Q3 2026, buying an estimated $39K and bringing the position to 259 shares worth $60K. The position accounts for 0.02% of the portfolio, ranked #333.

Elevation Wealth Partners first reported a position in JAZZ in Q2 2026 and has held it in 2 quarters since. 331 funds tracked by Wall St. Rank hold JAZZ as of Q3 2026.

  • Elevation Wealth Partners held 259 shares of Jazz Pharmaceuticals worth $60K as of Q3 2026.
  • Elevation Wealth Partners bought 158 Jazz Pharmaceuticals shares in Q3 2026, an estimated $39K.
  • Jazz Pharmaceuticals made up 0.02% of Elevation Wealth Partners's portfolio in Q3 2026, its #333 holding.
  • Elevation Wealth Partners first reported a position in Jazz Pharmaceuticals in Q2 2026 and has held it in 2 quarters since.
  • 331 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q3 2026.

Based on Elevation Wealth Partners's 13F filing for Q3 2026, filed 7 Oct 2026.